Arkadios Wealth Advisors’s iShares US Pharmaceuticals ETF IHE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q4
Sell
-1,422
Closed -$86K 1148
2021
Q3
$86K Sell
1,422
-99
-7% -$6.29K 0.01% 722
2021
Q2
$94K Buy
1,521
+3
+0.2% +$182 0.01% 735
2021
Q1
$89K Buy
1,518
+6
+0.4% +$362 0.01% 559
2020
Q4
$90K Buy
1,512
+108
+8% +$6.16K 0.02% 455
2020
Q3
$79.4K Buy
1,404
+3
+0.2% +$162 0.04% 329
2020
Q2
$73.5K Hold
1,401
0.04% 311
2020
Q1
$62.8K Buy
1,401
+6
+0.4% +$303 0.04% 304
2019
Q4
$74.9K Buy
+1,395
New +$68.8K 0.04% 269

Other funds holding IHE

Arkadios Wealth Advisors's IHE Position: Q4 2021 in Review

Arkadios Wealth Advisors sold out of iShares US Pharmaceuticals ETF (IHE) in Q4 2021, closing a stake of 1,422 shares — an estimated $86K sold.

Arkadios Wealth Advisors first reported a position in IHE in Q4 2019 and held it in 8 quarters. The position peaked at $94K in Q2 2021. 112 funds tracked by Wall St. Rank hold IHE as of Q4 2021.

  • Arkadios Wealth Advisors reported no remaining iShares US Pharmaceuticals ETF position as of Q4 2021 after selling out during the quarter.
  • Arkadios Wealth Advisors sold 1,422 iShares US Pharmaceuticals ETF shares in Q4 2021, an estimated $86K.
  • Arkadios Wealth Advisors first reported a position in iShares US Pharmaceuticals ETF in Q4 2019 and held it in 8 quarters.
  • Arkadios Wealth Advisors's iShares US Pharmaceuticals ETF position peaked at $94K in Q2 2021.
  • 112 funds tracked by Wall St. Rank held iShares US Pharmaceuticals ETF as of Q4 2021.

Based on Arkadios Wealth Advisors's 13F filing for Q4 2021, filed 3 Feb 2022.